

Spike glycoprotein of SARS-CoV-2 binds ACE2 on host cell

Acencio, ML., Gillespie, ME.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/licenses/).

29/04/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88

This document contains 1 reaction ([see Table of Contents](#))


Spike glycoprotein of SARS-CoV-2 binds ACE2 on host cell [↗](#)

Stable identifier: R-HSA-9694579

Type: binding

Compartments: plasma membrane

Diseases: COVID-19



SARS-CoV-2 spike protein trimer (S3), as a component of the S3:M:E:encapsidated SARS coronavirus-2 genomic RNA: 7a:O-glycosyl 3a tetramer complex, binds to glycosylated angiotensin converting enzyme 2 (ACE2) associated with the human host cell plasma membrane (Zhang et al, 2020; Raghuvamsi et al, 2021; reviewed by Jackson et al, 2022). Glycosylation of both molecules is the most important factor in their interaction (reviewed by Reis et al, 2021; Shajahan et al, 2021; Gong et al, 2021). Spike binding to ACE2 also requires the presence of heparan sulfate (HS) on the cell surface, consistent with the formation of a ternary complex between S, ACE2, and heparan sulfate proteoglycans (HSPGs) (Kim et al, 2020; Zhang et al, 2020; Clausen et al, 2021; Liu et al, 2021; Yue et al, 2021; Bermejo-Jambrina et al, 2021).

In SARS-CoV-1 structural studies of the interaction between human ACE2 protein and the receptor-binding domain of S3 protein have identified key amino acid residues in both proteins responsible for their high-affinity interaction. These residues may be a key factor determining severity (and possibly human-to-human transmission) of SARS-CoV-1 (Li et al. 2003, 2005). The roles of S protein in viral binding to the host cell membrane and fusion of viral and host cell membranes and thus the central role of S protein in determining the host range and tissue tropisms of the virus are reviewed by Belouzard et al. (2012) and Jackson et al. (2022).

Literature references

- Geijtenbeek, TBH., Spaargaren, M., Bermejo-Jambrina, M., van Hamme, JL., van Gils, MJ., Brouwer, PJM. et al. (2021). Infection and transmission of SARS-CoV-2 depend on heparan sulfate proteoglycans. *EMBO J*, 40, e106765. [↗](#)
- Linhardt, RJ., Zhang, F., Woods, RJ., Fu, L., Sood, A., Kim, SY. et al. (2020). Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. *Antiviral Res*, 181, 104873. [↗](#)
- Swaroop, M., Huang, W., Ye, Y., Shen, M., Hagen, N., Wang, AQ. et al. (2020). Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. *Cell Discov*, 6, 80. [↗](#)
- Qin, S., Gong, Y., Tian, Z., Dai, L. (2021). The glycosylation in SARS-CoV-2 and its receptor ACE2. *Signal Transduct Target Ther*, 6, 396. [↗](#)
- Jackson, CB., Farzan, M., Choe, H., Chen, B. (2022). Mechanisms of SARS-CoV-2 entry into cells. *Nat Rev Mol Cell Biol*, 23, 3-20. [↗](#)

Editions

2020-09-09	Reviewed	Acencio, ML.
2020-09-09	Authored, Edited	Gillespie, ME.